loader from loading.io

Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

OT Broadcast News

Release Date: 04/08/2010

Straight Talk with Dr. Brian J. Bolwell: Values show art Straight Talk with Dr. Brian J. Bolwell: Values

OT Broadcast News

Welcome to the Oncology Times Podcast. Today on the Pod - Why do relatively few leaders live good values consistently? Why are so many people, especially in academic medicine, consumed with values that are emotion-based? We will discuss these ideas and more with Dr. Brian J. Bolwell, the Chairman of the Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner School of Medicine.  Today Dr. Bolwell revisits his Oncology Times column on “Values” and outlines how to grow from an individual-focused, emotion-based values system to living with more positive values.

info_outline
Straight Talk with Dr. Brian J. Bolwell: Moments show art Straight Talk with Dr. Brian J. Bolwell: Moments

OT Broadcast News

In his recurring Oncology Times column “Straight Talk: Today's Cancer Centers,” Brian J. Bolwell, MD dispenses wisdom on how to be a better leader. In this episode, Dr. Bolwell revisits his column “Moments,” and discusses how to foster vulnerability, create psychological safety on a team, and embrace joy.

info_outline
September 2010 show art September 2010

OT Broadcast News

info_outline
Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World' show art Multiple Myeloma: Big Survival Gains from Novel Agents 'in the Real World'

OT Broadcast News

Evangelos Terpos, speaking at the European Hematology Association 2010 Congress in Barcelona, discusses his group's encouraging findings based on 10 years of experience with thalidomide, lenalidomide, and bortezomib.

info_outline
From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)  show art From the European Hematology Association 2010 Congress: For Patients with Follicular Lymphoma, Rituximab Maintenance Therapy Cuts Risk of Recurrence in Half (Phase III PRIMA Study)

OT Broadcast News

Speaking at the meeting in Barcelona, Gilles Salles of the University of Lyon discusses the results showing that patients who had achieved remissions after immunochemotherapy had only half the risk of recurrence if they also received rituximab maintenance therapy for two years compared with patients who did not.

info_outline
OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS show art OT Clinical Advisory Editor for Hematology/Oncology Mikkael Sekeres, MD, MS

OT Broadcast News

Dr. Sekeres, Director of the Leukemia Program at the Cleveland Clinic Taussig Cancer Institute and Chair of the Hematology/Oncology Pharmacy & Therapeutics Committee, discusses his particular research interests of myelodysplastic syndromes and acute myelogenous leukemia, including the overlaps between the two in older adults, new opportunities to better define MDS epidemiologically in the US, and new treatment approaches.

info_outline
OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD show art OT Clinical Advisory Editor for Oncology Ramaswamy Govindan, MD

OT Broadcast News

Dr. Govindan, Professor of Medicine and Director of the Thoracic Medical Oncology Program at Washington University Alvin J. Siteman Cancer Center, elaborates on his article in the April 10 issue about the promise and excitement of the new advances in technology that are now making possible a “panoramic view of the rugged genomic landscape of the cancer cell,” transforming cancer research and treatment.

info_outline
Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference  show art Treatment Recommendations for High- & Low-Risk Early Breast Cancer: New Data from EBCC 7, the European Breast Cancer Conference

OT Broadcast News

Lori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1 & 2 carriers; Annette Heemskerk-Gerritsen on the relationship between contralateral mastectomy & survival; and a recommendation by Ajay Sahu for a "cooling off" period for low-risk patients thinking of having prophylactic contralateral mastectomy.

info_outline
Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference  show art Pregnancy & Breast Cancer: New Updates from EBCC 7, the European Breast Cancer Conference

OT Broadcast News

Oncology Times  Hatem Azim on how pregnancy after breast cancer is safe and possibly protective; Angela Ives on why recent -- but not current -- pregnancy worsens breast cancer prognosis; and Sibylle Loibl on how chemotherapy is not generally hazardous to the fetus. Martine Piccart adds commentary & perspective

info_outline
Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome show art Longer Follow-up Reveals: Aspirin Prevents Cancer in Lynch Syndrome

OT Broadcast News

John Burn talking at ECCO15-ESMO34 in Berlin about his international study showing that aspirin prevented the development of Hereditary Non-Polyposis Colon Cancer in people genetically at risk for the disease.

info_outline
 
More Episodes

Lori Pierce on breast-conserving therapy + adjuvant chemotherapy for BRCA 1 & 2 carriers; Annette Heemskerk-Gerritsen on the relationship between contralateral mastectomy & survival; and a recommendation by Ajay Sahu for a "cooling off" period for low-risk patients thinking of having prophylactic contralateral mastectomy.